Tackling muscle fibrosis: From molecular mechanisms to next generation engineered models to predict drug delivery

S. Bersini, M. Gilardi, M. Mora, S. Krol, C. Arrigoni, C. Candrian, S. Zanotti, M. Moretti

Research output: Contribution to journalReview article

Abstract

Muscle fibrosis represents the end stage consequence of different diseases, among which muscular dystrophies, leading to severe impairment of muscle functions. Muscle fibrosis involves the production of several growth factors, cytokines and proteolytic enzymes and is strictly associated to inflammatory processes. Moreover, fibrosis causes profound changes in tissue properties, including increased stiffness and density, lower pH and oxygenation. Up to now, there is no therapeutic approach able to counteract the fibrotic process and treatments directed against muscle pathologies are severely impaired by the harsh conditions of the fibrotic environment. The design of new therapeutics thus need innovative tools mimicking the obstacles posed by the fibrotic environment to their delivery. This review will critically discuss the role of in vivo and 3D in vitro models in this context and the characteristics that an ideal model should possess to help the translation from bench to bedside of new candidate anti-fibrotic agents.

Original languageEnglish
Pages (from-to)64-77
Number of pages14
JournalAdvanced Drug Delivery Reviews
Volume129
DOIs
Publication statusPublished - Apr 1 2018

Keywords

  • 3D in vitro models
  • Muscular dystrophy
  • Skeletal muscle fibrosis

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Tackling muscle fibrosis: From molecular mechanisms to next generation engineered models to predict drug delivery'. Together they form a unique fingerprint.

  • Cite this